Success Stories: Chinese Student Earns NIW Approval for Alzheimer’s Disease Biomarker and Lipidomics Research

On October 7^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Student in the field of Biochemistry (Approval Notice).

General Field: Biochemistry

Position at the Time of Case Filing: Student

Country of Origin: China

State of Residence at the Time of Filing: New Jersey

Approval Notice Date: October 7^th, 2025

Processing Time: 1 month, 22 days (Premium Processing Requested)

Case Summary:

We are pleased to share the NIW approval of a student from China. At the time of filing, the client was conducting research in the United States focused on developing advanced mass spectrometry (MS) and lipidomic techniques to uncover the biochemical basis of Alzheimer’s disease (AD). His studies aim to identify early-stage biomarkers and therapeutic targets to improve diagnosis and treatment. With a strong record of publications, citations, and research support from leading institutions, he was a highly qualified candidate for NIW approval.

Research with National Importance

The client’s research integrates MS-based lipidomics and bioinformatics to identify biochemical mechanisms underlying AD progression. His work has revealed lipid imbalances associated with neuronal dysfunction and insulin resistance, providing new insight into disease development and biomarker discovery.

As Alzheimer’s disease affects millions of Americans and contributes substantially to national healthcare costs, his research directly supports U.S. priorities in neurological disease prevention and public health innovation. His findings also align with initiatives of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to advance early detection and treatment of neurodegenerative disorders.

Academic Achievements and Recognition

The client holds a master’s degree in chemistry and has authored 6 peer-reviewed journal articles and 3 book chapters, including publications in Nature Communications, The EMBO Journal, and JCI Insight. His work has been cited nearly 400 times by independent researchers, with four papers ranking among the top 1–10% most cited in biochemistry for their publication years.

He has also contributed to federally funded projects supported by the NIH, the National Institute of Aging, and the National Institute of Diabetes and Digestive and Kidney Diseases, endorsements that underscore the national relevance of his work.

Expert Recognition

Independent experts commended the client’s contributions to biochemistry and neurodegenerative disease research.

One recommender noted:

“In sum, [client] is a respected neuroscience researcher who has enhanced mass spectrometry technology in biomedical and neuroscientific research to support the biotechnology industry and, resultantly, strengthen the national economy.”

This statement reflects both the originality and the clinical value of his research.

NIW Approval and Outlook

The I-140 NIW petition was filed on August 15, 2025, and approved on October 7, 2025, under premium processing. With NAILG’s guidance, the client successfully demonstrated the national significance of his lipidomics and Alzheimer’s research.

He now continues his work in the United States, applying advanced MS techniques and computational tools to develop biomarker-driven strategies for early Alzheimer’s detection. His ongoing research supports the nation’s broader efforts to improve public health, biomedical innovation, and disease prevention.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.